Virbac

Q3 crushed doubts about execution ability

17/10/25 -"The markets were jubilant with Virbac’s Q3 25 beat and a guidance upgrade, especially because the investors, in September 2025, doubted the firm’s ability to meet its previous full-year ..."

PDF page sample
Pages
54
Language
English
Published on
17/10/25
Download
You may also be interested by these reports :
17/10/25
The markets were jubilant with Virbac’s Q3 25 beat and a guidance upgrade, especially because the investors, in September 2025, doubted the firm’s ...
06/10/25
Over the week ending 3 October, equity markets delivered another strong performance. In Europe, the STOXX 600 rose 2.9%, driven by a massive rebound ...
03/10/25
We have materially upgraded our earnings estimates for UCB, keeping in view the vigorous uptake of the immunology drug Bimzelx, and a strong support ...
29/09/25
Genmab is strategically acquiring Merus to expand its late-stage portfolio with head and neck cancer treatments, addressing anticipated declines in ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO